D
Dana A. Kennedy
Researcher at Seattle Genetics
Publications - 47
Citations - 5373
Dana A. Kennedy is an academic researcher from Seattle Genetics. The author has contributed to research in topics: Brentuximab vedotin & Monomethyl auristatin E. The author has an hindex of 26, co-authored 47 publications receiving 4967 citations.
Papers
More filters
Journal ArticleDOI
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes,Ajay K. Gopal,Scott E. Smith,Stephen M. Ansell,Joseph D. Rosenblatt,Kerry J. Savage,Radhakrishnan Ramchandren,Nancy L. Bartlett,Bruce D. Cheson,Sven de Vos,Andres Forero-Torres,Craig H. Moskowitz,Joseph M. Connors,Andreas Engert,Emily K. Larsen,Dana A. Kennedy,Eric L. Sievers,Robert T. Chen +17 more
TL;DR: The ADC brentuximab vedotin was associated with manageable toxicity and induced objective responses in 75% of patients with relapsed or refractory HL after autologous stem-cell transplantation (auto-SCT).
Journal ArticleDOI
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Anas Younes,Nancy L. Bartlett,John P. Leonard,Dana A. Kennedy,Carmel M. Lynch,Eric L. Sievers,Andres Forero-Torres +6 more
TL;DR: Brentuximab vedotin induced durable objective responses and resulted in tumor regression for most patients with relapsed or refractory CD30-positive lymphomas in this phase 1 study.
Journal ArticleDOI
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Barbara Pro,Ranjana H. Advani,Pauline Brice,Nancy L. Bartlett,Joseph D. Rosenblatt,Timothy M Illidge,Jeffrey Matous,Radhakrishnan Ramchandren,Michelle A. Fanale,Joseph M. Connors,Yin Yang,Eric L. Sievers,Dana A. Kennedy,Andrei R. Shustov +13 more
TL;DR: Targeted therapy with this CD30-directed antibody-drug conjugate brentuximab vedotin may be an effective treatment for relapsed or refractory systemic ALCL and warrants further studies in front-line therapy.
Journal ArticleDOI
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin
Steven M. Horwitz,Ranjana H. Advani,Nancy L. Bartlett,Eric D. Jacobsen,Jeff P. Sharman,Owen A. O'Connor,Tanya Siddiqi,Dana A. Kennedy,Yasuhiro Oki +8 more
TL;DR: In summary, brentuximab vedotin showed antitumor activity in patients with relapsed PTCL particularly AITL, and safety data were consistent with the known profile of brentUXimabvedotin.
Journal ArticleDOI
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression
Eric D. Jacobsen,Jeff P. Sharman,Yasuhiro Oki,Ranjana H. Advani,Jane N. Winter,Celeste M. Bello,Gary Spitzer,Maria Corinna Palanca-Wessels,Dana A. Kennedy,Pamela Levine,Jing Yang,Nancy L. Bartlett +11 more
TL;DR: Overall, significant activity with brentuximab vedotin was observed in relapsed/refractory DLBCL, and responses occurred across a range of CD30 expression.